Multiple sclerosis (MS) may occur before the age of 18. Differentiation between paediatric MS (PedMS) and other demyelinating syndromes (ODSs) is challenging. In adult with MS, the kappa free light chain (KFLC) index has proven to be a reliable marker of intrathecal Ig synthesis.
Objective:
To assess the diagnostic value of the KFLC index in a cohort of patients with paediatric-onset, inflammatory disorders of the CNS.
Methods:
We included 73 patients and divided them into four groups: PedMS (n = 16), ODS (n = 17), encephalitis and/or inflammatory epilepsy (EE, n = 15), and controls without inflammatory CNS diseases (n = 25). The KFLC index was calculated and compared with the results of the oligoclonal bands determination.
Results:
The KFLC index was higher in the PedMS group (median (interquartile range (IQR)): 150.9 (41.02–310.6)) than in the ODS (3.37 (2.22–8.11)), the EE (5.53 (2.31–25.81)) and the control group (3.41 (2.27–5.08)), respectively. The best KFLC index cut-off for differentiating between patients with PedMS and controls was 6.83 (sensitivity: 100%; specificity: 92%). A KFLC index over 93.77 indicated that the patient is very likely to have PedMS (sensitivity: 68%; specificity: 100%).
Conclusion:
The KFLC index is a reliable tool for the diagnosis of MS in a paediatric population.
BoikoAVorobeychikGPatyD, et al. Early onset multiple sclerosis: A longitudinal study. Neurology2002; 59(7): 1006–1010.
2.
AlroughaniRBoykoA. Pediatric multiple sclerosis: a review. BMC Neurol2018; 18(1): 27.
3.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17(2): 162–173.
4.
HegenHArrambideGGnanapavanS, et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement. Mult Scler J2023; 29(2): 182–195.
5.
LevrautMLaurent-ChabalierSAyrignacX, et al. Kappa free light chain biomarkers are efficient for the diagnosis of multiple sclerosis: A large multicenter cohort study. Neurol Neuroimmunol Neuroinflammation2023; 10(1): e200049.
6.
MarlasMBostCDorcetG, et al. Kappa-index: Real-life evaluation of a new tool for multiple sclerosis diagnosis. Clin Immunol2022; 241: 109066.
7.
LevrautMGavoilleALandes-ChateauC, et al. Kappa free light chain index predicts disease course in clinically and radiologically isolated syndromes. Neurol Neuroimmunol Neuroinflammation2023; 10(6): e200156.
8.
FerraroDBedinRNataliP, et al. Kappa index versus CSF oligoclonal bands in predicting multiple sclerosis and infectious/inflammatory CNS disorders. Diagnostics2020; 10(10): 856.
9.
FerraroDTrovatiABedinR, et al. Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis. Eur J Neurol2020; 27(3): 461–467.
10.
HegenHWaldeJBerekK, et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. Mult Scler J2023; 29(2): 169–181.
11.
KruppLBTardieuMAmatoMP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler J2013; 19(10): 1261–1267.
12.
ReiberHZemanDKušnierováP, et al. Diagnostic relevance of free light chains in cerebrospinal fluid – The hyperbolic reference range for reliable data interpretation in quotient diagrams. Clin Chim Acta2019; 497: 153–162.
13.
WaldMMerisorSZacharyP, et al. Microbiological outcomes associated with low leukocyte counts in cerebrospinal fluid. Open Forum Infect Dis2021; 8(2): ofaa597.
14.
HacohenYSinghRForsythV, et al. CSF albumin and immunoglobulin analyses in childhood neurologic disorders. Neurol Neuroimmunol Neuroinflammation2014; 1(1): e10.
15.
SenelMTumaniHLaudaF, et al. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS ONE2014; 9(4): e88680.
16.
Menéndez-ValladaresPGarcía-SánchezMIAdorna MartínezM, et al. Validation and meta-analysis of kappa index biomarker in multiple sclerosis diagnosis. Autoimmun Rev2019; 18(1): 43–49.
17.
HegenHMilosavljevicDSchnablC, et al. Cerebrospinal fluid free light chains as diagnostic biomarker in neuroborreliosis. Clin Chem Lab Med CCLM2018; 56(8): 1383–1391.
18.
CohenSBannisterR. Immunoglobulin synthesis within the central nervous system in disseminated sclerosis. The Lancet1967; 289(7486): 366–367.
19.
JohnsonKPNelsonBJ. Multiple sclerosis: Diagnostic usefulness of cerebrospinal fluid. Ann Neurol1977; 2(5): 425–431.
20.
RosensteinIAxelssonMNovakovaL, et al. Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis. J Neurol2023; 270(10): 4800–4811.
21.
DeschampsRShorNPapeixC, et al. Relevance of kappa free light chains index in patients with aquaporin-4 or myelin-oligodendrocyte-glycoprotein antibodies. Eur J Neurol2023; 30(9): 2865–2869.
22.
Alves MartinsDLopesJMartins Da SilvaA, et al. Kappa free light chains: Diagnostic performance in multiple sclerosis and utility in a clinical laboratory. Clin Chim Acta2022; 528: 56–64.
23.
Tortosa-CarreresJQuiroga-VarelaACastillo-VillalbaJ, et al. Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm. Mult Scler Relat Disord2023; 79: 104997.
24.
Valencia-VeraEMartinez-Escribano Garcia-RipollAEnguixA, et al. Application of κ free light chains in cerebrospinal fluid as a biomarker in multiple sclerosis diagnosis: development of a diagnosis algorithm. Clin Chem Lab Med CCLM2018; 56(4): 609–613.
25.
RosensteinIRaschSAxelssonM, et al. Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real-world investigation. J Neurochem2021; 159(3): 618–628.
26.
PuthenparampilMFederleLMianteS, et al. BAFF index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset. J Neuroinflammation2017; 14(1): 11.
27.
PitteriMMagliozziRNicholasR, et al. Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients. Mult Scler J2022; 28(5): 768–777.
28.
KhalilMTeunissenCEOttoM, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol2018; 14(10): 577–589.
29.
LyckeJZetterbergH. The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis. Expert Rev Clin Immunol2017; 13(12): 1143–1153.
30.
BenkertPMeierSSchaedelinS, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol2022; 21(3): 246–257.
31.
AlagaratnamJVon WidekindSDe FrancescoD, et al. Correlation between CSF and blood neurofilament light chain protein: A systematic review and meta-analysis. BMJ Neurol Open2021; 3(1): e000143.
